QTRX
NASDAQQuanterix Corporation
Price$2.87-0.16 (-5.45%)
01:30 PM07:45 PM
News · 26 weeks62+20%
2026-04-192026-10-11
Mix2490d
- Insider12(50%)
- Other8(33%)
- Earnings2(8%)
- SEC Filings2(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Quanterix Corporation4 - Quanterix Corp (0001503274) (Issuer)
- PRQuanterix and Innovita Expand IVD Access in China with National Medical Products Administration ApprovalsNMPA approvals for Quanterix SIMOA® instruments and key neurology biomarker assays advance access to ultra-sensitive blood-based testing in China Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced regulatory approvals that advance access to the Quanterix SIMOA® technology and neurology biomarker testing in the Chinese market. Initially formed in 2024, the commercialization arrangement combines Quanterix’s ultra-sensitive biomarker detection technology with Innovita’s diagnostics development, regulatory and commercialization cap
- INSIDERDirector Magovcevic-Liebisch Ivana converted options into 4,224 shares, increasing direct ownership by 36% to 15,883 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERDirector Mendel Scott was granted 4,398 shares, increasing direct ownership by 18% to 28,454 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERDirector Donnelly William P was granted 6,964 shares, increasing direct ownership by 4% to 169,365 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- PRQuanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026Molecular Barcoding Kit Now Available Globally; TIME and high-plex ADC panels confirmed for Q4 shipment; Accelerator Laboratory Services open custom ADC panel development Quanterix Corporation (NASDAQ:QTRX) today reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology (ESSB) September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on the integration of Akoya Biosciences' spatial biology platform and
- INSIDERSEC Form 4 filed by Chief Commercial Officer Gute James Edward Jr.4 - Quanterix Corp (0001503274) (Issuer)
- PRQuanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the "Inducement Grants") were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units ("RSUs") representing 260,315 shares of Quanterix common stock. The Inducement Grants to the other two employees consisted of 365,326 RSUs in the aggregate representing 365,326 shares of Quanterix common stock. The RSUs vest in four equal annual installments on the first four
- INSIDERChief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 38,452 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- PRQuanterix Names Dr. Yuri Fesko Chief Medical OfficerQuanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company’s Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix’s innovative technologies and applications. "As we prepare for the broader market launch of our Lucent AD® Complete five biomarker test for Alzheimer’s Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our efforts to efficiently scale our expans
- INSIDERChief Technology Officer Miller Michael Francis converted options into 159 shares and covered exercise/tax liability with 48 shares, increasing direct ownership by 0.30% to 37,361 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERDirector Elliott Jeffrey Thomas converted options into 3,955 shares, increasing direct ownership by 35% to 15,345 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gute James Edward Jr.3 - Quanterix Corp (0001503274) (Issuer)
- INSIDERDirector Donnelly William P converted options into 2,802 shares, increasing direct ownership by 2% to 162,401 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERChief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 37,250 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quanterix CorporationSCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)
- SECSEC Form 10-Q filed by Quanterix Corporation10-Q - Quanterix Corp (0001503274) (Filer)
- SECQuanterix Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Quanterix Corp (0001503274) (Filer)
- PRQuanterix Names Jim Gute Chief Commercial OfficerBrings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company’s commercial operations. "We are thrilled to attract commercial leadership of Jim’s caliber to Quanterix, at a pivotal time, ahead of our expansion in diagnostics and with renewed focus on growing our core business," said Everett Cunningham, President & CEO of Quanterix. "Jim brings the expertise we ne
- PRQuanterix Releases Financial Results for the Second Quarter of 2026Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends date for attaining cash-flow break-even Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. "We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness. We are taking immediate and significant a
- SECSEC Form SCHEDULE 13G filed by Quanterix CorporationSCHEDULE 13G - Quanterix Corp (0001503274) (Subject)
- PRQuanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat that will be webcast live on 1:00 pm ET on Wednesday, August 12th, during which he will provide an update on the Company and its strategic priorities. Chief Technology and Product Officer Michael Miller will join a panel discussion on Neurology Diagnostics at 2:00 pm ET the same day. The Company is also scheduling one-on-one investor meetings bot
- INSIDERChief Technology Officer Miller Michael Francis converted options into 130 shares and covered exercise/tax liability with 39 shares, increasing direct ownership by 0.25% to 36,159 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- PRQuanterix To Report Second Quarter 2026 Financial Results on August 10, 2026Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026 financial results. Quanterix will issue a press release regarding its second quarter 2026 financial results prior to the conference call on Monday, August 10, 2026. The press release will be posted on the Quanterix website at http://www.quanterix.com/. In conjunction with this announcement, the Company will host a conference call on August 10, 2026, at 8:30 AM ET. The dial-in number for USA & Canada is Toll-Free (800) 715-9871 or (646) 307-1963 and the conference ID is 989691
- INSIDERChief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 36,068 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
QTRX FAQ
7 questionsWhat does Quanterix Corporation do?
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the...Where does QTRX stock trade?
Quanterix Corporation (QTRX) is listed on NASDAQ.What sector and industry is QTRX in?
Quanterix Corporation operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Quanterix Corporation go public?
Quanterix Corporation (QTRX) completed its IPO in 2017.What are analysts saying about QTRX?
Quanterix Corporation has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Hold with a $500.00 price target on 2025-08-11.What companies are similar to QTRX?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare QTRX side-by-side with any of them on Quantisnow.How can I track QTRX on Quantisnow?
Quantisnow aggregates Quanterix Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QTRX to receive live email and push alerts on every new disclosure.